More than two decades ago, the concept of tissue engineering predicted the healing of injured tissues and organs by the use of living cells and/or smart functional materials. The approaches taken to recreate tissues and organs have typically involved a combination of cells, materials and bioactive molecules. Combining all the components involved in tissue repair, the hypothesis that "bench neo-created tissue", upon implantation could lead to host native tissue homeostatic state and by consequence restore from the very first beginning functionalities lost with time due to trauma or disease has gained more clear evidences [1] .
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Considering the high multifaceted biological environment of cartilage it is clearly indicated that understanding the cellular interactions that regulate cartilaginous homeostasis under physiological and inflammatory conditions is a keystone and necessary for successful cartilage regeneration. In the complete process of inflammatory events on chondrocytes, the only cellular type present in articular cartilage have become the focus of several lines of investigation driven by tissue engineering, basic and clinical research [2] .
In this context, Van Vulpen et al [3] recently described the importance of blood-provided pro-inflammatory cytokines on trigger chondrocytes induction of cartilage-degrading proteases and the effect of recombinant antibodies on the reduction of it. The authors described that human IL-1β monoclonal antibody or IL-1 receptor antagonist addition is dose and time dependent, protects cartilage from blood-induced damage. Effects on reduction of inflammation were accompanied with decrease production of IL-1β and IL-6 and maintenance of TNF-α. Results disclosed that IL-1β is crucial in the development of blood-induced joint damage, whereas TNF-α is not. These novel evidences demonstrated the hierarchical position of IL-1β in blood-induced joint damage and the potential use of it to prevent joint degeneration in a bleed environment.
